503 related articles for article (PubMed ID: 20047862)
21. Treatment of poor-prognosis sex cord-stromal tumors of the ovary with the combination of bleomycin, etoposide, and cisplatin.
Gershenson DM; Morris M; Burke TW; Levenback C; Matthews CM; Wharton JT
Obstet Gynecol; 1996 Apr; 87(4):527-31. PubMed ID: 8602303
[TBL] [Abstract][Full Text] [Related]
22. A phase II evaluation of high dose cisplatin and etoposide in patients with advanced esophageal adenocarcinoma.
Spiridonidis CH; Laufman LR; Jones JJ; Gray DJ; Cho CC; Young DC
Cancer; 1996 Nov; 78(10):2070-7. PubMed ID: 8918399
[TBL] [Abstract][Full Text] [Related]
23. Cisplatin plus etoposide chemotherapy followed by thoracic irradiation and paclitaxel plus cisplatin consolidation therapy for patients with limited stage small cell lung carcinoma.
Kakolyris S; Agelidou A; Androulakis N; Tsaroucha E; Kouroussis Ch; Agelidou M; Karvounis N; Veslemes M; Christophylakis Ch; Argyraki A; Geroyianni A; Georgoulias V
Lung Cancer; 2006 Jul; 53(1):59-65. PubMed ID: 16716447
[TBL] [Abstract][Full Text] [Related]
24. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck.
Okuno SH; Mailliard JA; Suman VJ; Edmonson JH; Creagan ET; Nair S; Levitt R; Kugler JW
Cancer; 2002 Apr; 94(8):2224-31. PubMed ID: 12001121
[TBL] [Abstract][Full Text] [Related]
26. Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer. Japanese Lung Cancer Chemotherapy Group in Japanese Clinical Oncology Group.
Ariyoshi Y; Fukuoka M; Furuse K; Saijo N; Ikegami H; Nishiwaki Y; Tamura T; Shimoyama M; Suemasu K
Jpn J Clin Oncol; 1994 Oct; 24(5):275-81. PubMed ID: 7967106
[TBL] [Abstract][Full Text] [Related]
27. First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: a single institution experience.
Olsen IH; Langer SW; Jepsen I; Assens M; Federspiel B; Hasselby JP; Hansen CP; Kjaer A; Knigge U
Acta Oncol; 2012 Jan; 51(1):97-100. PubMed ID: 21615243
[TBL] [Abstract][Full Text] [Related]
28. Activity of a three-drug combination including cisplatin (CLOVER regimen) for poorly differentiated neuroendocrine carcinoma.
Bajetta E; Catena L; Biondani P; Pusceddu S; Valente M; Bianco N; Novelli E
Anticancer Res; 2014 Oct; 34(10):5657-60. PubMed ID: 25275070
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of oral etoposide in combination with cisplatin for patients with recurrent cervical cancer: long-term follow-up results of a Japanese multicenter study.
Watanabe Y; Hoshiai H; Nakanishi T; Kawamura N; Tanaka N; Isaka K; Kamiura S; Ohmichi M; Hatae M; Ochiai K
Anticancer Res; 2011 Sep; 31(9):3063-7. PubMed ID: 21868560
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and Safety of Carboplatin and Etoposide Combination Chemotherapy for Extrapulmonary Neuroendocrine Carcinoma: A Retrospective Case Series.
Imai H; Shirota H; Okita A; Komine K; Saijo K; Takahashi M; Takahashi S; Takahashi M; Shimodaira H; Ishioka C
Chemotherapy; 2016; 61(3):111-6. PubMed ID: 26636658
[TBL] [Abstract][Full Text] [Related]
31. Feasibility and efficacy of combined cisplatin and irinotecan chemotherapy for poorly differentiated neuroendocrine carcinomas.
Nakano K; Takahashi S; Yuasa T; Nishimura N; Mishima Y; Sakajiri S; Yokoyama M; Tsuyama N; Ishikawa Y; Hatake K
Jpn J Clin Oncol; 2012 Aug; 42(8):697-703. PubMed ID: 22701038
[TBL] [Abstract][Full Text] [Related]
32. Good performance of platinum-based chemotherapy for high-grade gastroenteropancreatic and unknown primary neuroendocrine neoplasms.
Brandi G; Paragona M; Campana D; Brighi N; Bondi A; Pantaleo MA; Corbelli J; Barbera MA; Biasco G
J Chemother; 2018 Feb; 30(1):53-58. PubMed ID: 28641483
[TBL] [Abstract][Full Text] [Related]
33. Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with liver metastases of digestive endocrine carcinomas.
Hentic O; Couvelard A; Rebours V; Zappa M; Dokmak S; Hammel P; Maire F; O'Toole D; Lévy P; Sauvanet A; Ruszniewski P
Endocr Relat Cancer; 2011 Feb; 18(1):51-9. PubMed ID: 20959440
[TBL] [Abstract][Full Text] [Related]
34. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy.
Welin S; Sorbye H; Sebjornsen S; Knappskog S; Busch C; Oberg K
Cancer; 2011 Oct; 117(20):4617-22. PubMed ID: 21456005
[TBL] [Abstract][Full Text] [Related]
35. Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy.
Nio K; Arita S; Isobe T; Kusaba H; Kohashi K; Kajitani T; Tamura S; Hirano G; Mitsugi K; Makiyama A; Esaki T; Ariyama H; Oda Y; Akashi K; Baba E
Cancer Chemother Pharmacol; 2015 Apr; 75(4):829-35. PubMed ID: 25702050
[TBL] [Abstract][Full Text] [Related]
36. A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small cell lung cancer).
Kenmotsu H; Niho S; Ito T; Ishikawa Y; Noguchi M; Tada H; Sekine I; Watanabe S; Yoshimura M; Yamamoto N; Oshita F; Kubota K; Nagai K
Lung Cancer; 2014 Jun; 84(3):254-8. PubMed ID: 24679951
[TBL] [Abstract][Full Text] [Related]
37. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors.
Fjällskog ML; Granberg DP; Welin SL; Eriksson C; Oberg KE; Janson ET; Eriksson BK
Cancer; 2001 Sep; 92(5):1101-7. PubMed ID: 11571721
[TBL] [Abstract][Full Text] [Related]
38. [Poorly-differentiated neuroendocrine carcinoma of ascending colon with liver metastases successfully treated with carboplatin and etoposide].
Akiyama S; Niitani T; Narasaka T; Ohto T; Gamoh M
Gan To Kagaku Ryoho; 2011 Jul; 38(7):1209-12. PubMed ID: 21772114
[TBL] [Abstract][Full Text] [Related]
39. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin.
Mitry E; Baudin E; Ducreux M; Sabourin JC; Rufié P; Aparicio T; Aparicio T; Lasser P; Elias D; Duvillard P; Schlumberger M; Rougier P
Br J Cancer; 1999 Dec; 81(8):1351-5. PubMed ID: 10604732
[TBL] [Abstract][Full Text] [Related]
40. Treatment of poorly differentiated neuroendocrine carcinoma of the pancreas.
Gupta A; Duque M; Saif MW
JOP; 2013 Jul; 14(4):381-3. PubMed ID: 23846932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]